Scholars Central

Conference abstractPublished 2 Jul 2019

Rediscovering clozapine

Authors: Jason A. Gross

Pharmaceutical Executive, Canada

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In 1989, clozapine was approved in the United States for Treatment-Resistant Schizophrenia (TRS), which after thirty years of use is still the only known treatment for TRS. In the United States, there are more than 3.5 million people living with schizophrenia, of which approximately 1 million have what is known as treatment-resistant schizophrenia. However, this treatment option is only offered to about 3% of eligible TRS patients are receiving treatment with clozapine. This lecture will explore the: (i) The perceived barriers to clozapine use (ii) Recent advances in clozapine care (iii) New technology for monitoring patients with TRS treated with clozapine (iv) Explore best practices for patients with TRS.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in International Journal of Emergency Mental Health and Human Resilience.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Emergency Mental Health and Human Resilience
  • SubjectMental Health and Psychology
  • BylineArticles whose byline prints “Jason A. Gross”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels